NEW YORK--(BUSINESS WIRE)--
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Ekso Bionics Holdings, Inc. (“Ekso” or the “Company”) (NASDAQ: EKSO) concerning whether the board has breached its fiduciary duties to shareholders.
On December 14, 2017, the Company disclosed that it suffered from material weaknesses to its internal controls over disclosure and that it would be required to amend its Form 10-K for the 2016 fiscal year and its Forms 10-Q for the first three quarters of 2017.
Our investigation concerns whether the Ekso board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.
If you own Ekso shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
| Robert I. Harwood, Esq. | ||
| Benjamin I. Sachs-Michaels, Esq. | ||
|
Harwood Feffer LLP |
||
| 488 Madison Avenue | ||
| New York, New York 10022 | ||
| Phone Numbers: | (877) 935-7400 | |
| (212)935-7400 | ||
|
Email: [email protected] |
||
|
Website: http://www.hfesq.com |
||
|
Follow us on Twitter: @HarwoodFeffer |
||
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180108006849/en/
